Serratia marcescens bacteremia.

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Hospital Epidemiology

Background:

• Serratia marcescens bacteremia is increasingly recognized as a significant clinical issue.
• Both hospital-acquired and community-acquired infections warrant attention due to potential severity.
• Previous understanding of S. marcescens bacteremia's impact and treatment may be outdated.

Purpose of the Study:

• To analyze the clinical characteristics and outcomes of Serratia marcescens bacteremia.
• To evaluate the sources of infection and identify risk factors.
• To assess the efficacy of different antibiotic treatments for nosocomial S. marcescens bacteremia.

Main Methods:

• Retrospective review of 23 episodes of S. marcescens bacteremia occurring in 1985.
• Categorization of infections into hospital-acquired versus community-acquired.
• Analysis of infection sources, patient outcomes, and antibiotic susceptibility patterns.

Main Results:

• A high case fatality rate of 39% was observed among the 23 patients.
• Hospital-acquired infections predominated (74%), with a significant proportion (48%) having no clear source.
• Amikacin and third-generation cephalosporins demonstrated superior efficacy compared to gentamicin for nosocomial infections.

Conclusions:

• Serratia marcescens bacteremia is a critical condition requiring heightened clinical awareness.
• Effective management necessitates prompt diagnosis and appropriate antibiotic therapy, particularly in nosocomial settings.
• Antibiotic resistance patterns underscore the importance of selecting effective agents like amikacin or third-generation cephalosporins.